Evidence map›Paper›PMID 24933097›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2014

Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort.

Valeria Saraceni, Silvia Cohn, Solange C Cavalcante, Antonio G F Pacheco, Lawrence H Moulton, Richard E Chaisson, Betina Durovni, Jonathan E Golub

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Record linkage in tuberculosis epidemiological surveillance in Brazil: systematic methodological literature review.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2026
    Pooled it
  2. Observational
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valeria Saraceni*Rio de Janeiro City Health Secretariat, Rio de Janeiro, Brazil; †Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD; ‡FIOCRUZ, PROCC, Rio de Janeiro, Brazil; §Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and ‖Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Silvia Cohn
Solange C Cavalcante
Antonio G F Pacheco
Lawrence H Moulton
Richard E Chaisson
Betina Durovni
Jonathan E Golub

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Innovative Approaches for Tuberculosis Control in BrazilU2RTW006885 · FIC · JOHNS HOPKINS UNIVERSITY · PI GOLUB, JONATHAN E. · 2005 to 2014
$2.3M
CLINICAL RESEARCH IN TUBERCULOSISK24AI001637 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHAISSON, RICHARD E. · 1999 to 2009
$1.3M
Epidemiologic Strategies for Tuberculosis ControlK01AI066994 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GOLUB, JONATHAN E. · 2005 to 2009
$564k
FIC NIH HHS U2R TW006885NIAID NIH HHS AI001637NIAID NIH HHS AI066994NIAID NIH HHS K01 AI066994NIAID NIH HHS K24 AI001637NIAID NIH HHS P30 AI094189PHS HHS 5U2RTW006885
6 · The paper itself

Abstract

backgroundAlthough Brazil has model HIV care programs, many patients continue to present late to care. We studied the frequency of tuberculosis (TB) diagnosed at HIV diagnosis in Rio de Janeiro, Brazil, to quantify missed opportunities for TB prevention.

methodsPeople living with HIV (PLHIV) and enrolled in the TB/HIV in Rio study between September 1, 2005, and August 31, 2009, were included. Prevalent TB was defined as TB diagnosed within 60 days of HIV diagnosis or HIV diagnosis during TB therapy. Survival was measured from HIV diagnosis. We conducted Kaplan-Meier survival plots and Cox regression analyses.

resultsFour thousand five hundred forty-eight newly diagnosed PLHIV were enrolled: 476 (10.5%) with prevalent TB. Individuals with prevalent TB were older, had lower CD4 counts, and higher viral loads than did those without TB. Median time to receiving highly active antiretroviral therapy (HAART) in those with prevalent TB was 99 days (interquartile range = 58-191) vs. 126 days (interquartile range = 63-301) in those without TB (P = 0.021). Among those with prevalent TB, 17% died during follow-up compared with 8% among those without TB (P < 0.001). After adjustment for sex, age, baseline CD4, and baseline viral load, the risk of occurrence of death remained significantly higher among those with prevalent TB [adjusted hazard ratio = 1.72 (confidence interval 95% 1.19 to 2.48)].

conclusionsMore than 10% of new PLHIV in our study presented to care with concurrent active TB disease and thus missed the opportunity for undergoing TB preventive therapy. Despite initiating HAART more quickly, these individuals were at a significantly greater risk of death. Earlier HIV diagnosis is necessary to provide earlier initiation of HAART and TB preventive therapy to reduce morbidity and mortality in PLHIV.

Indexed as

AdultAntiretroviral Therapy, Highly ActiveBrazilCD4 Lymphocyte CountCluster AnalysisCohort StudiesFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedPrevalenceProportional Hazards ModelsRegression AnalysisTuberculosis

Identifiers

PMID24933097
PMCPMC4497547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.